great progress ,let's hope at last that we remain on an upwards trajectory back to a Beigene/Innovent type valaution |
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, December 13, 2023: HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMEDR21;) today announces that it has completed enrollment of its Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China.
Let's hope we reach the 500p range again in 2024. We are not too far off the year's high but 2021 and the beginning of 2022 were much better periods as far as the share price goes! |
They are still burning 350musd a year in cash on r+d.
Whatever they say in annual reports it’s obvious that Covid set back sales by around 3years (looking at analysts’ spreadsheets for forward revenue etc from 2018/19 ). Latest projection for cash flow project positive from about 2025 , barring any more upsets (politics for example).
So the sale of some at least of the commercial operations may still be necessary , but it is a very good insurance policy and makes the capitalisation in the market look ridiculous. Basically all the pipeline is in there at 50% valuation… |
They dont need the money any more…..while they might say they have options, they really have no interest in selling except for an exceptional price.,,and that gives them a problem of what to do with the cash….they dont have any debt to speak of….so that would mean they would have to buy something else or return it to Shareholders. |
pity, I thouight it would be the sale of their JV which is worth circa $1bn.... |
sorry waldron thanks for that, I should have remembered |
Nerdofsteel
3 Dec '23 - 14:08 - 3961 of 3962
0 0 0
it seems there is means tested assistance for people on co-pay plans where their insure will not cover the cost or the full cost
Nerdofsteel
3 Dec '23 - 14:19 - 3962 of 3962
0 0 0
capital H Nerdo helps |
hxxps://www.stockilluminati.com/hcm/display.php?url=hxxps%3a%2f%2fwww.stockilluminati.com%2fhcm%2fsanews.html |
it seems there is means tested assistance for people on co-pay plans where their insure will not cover the cost or the full cost
hxxps://www.fruzaqla.com/ |
How many pay the full US price?
Won’t all the insurers/medicaid have significant discounts? |
A couple of recent bits:
(Published: 3:04pm, 29 Nov, 2023) “Fruquintinib, which will be marketed as Fruzaqla in the US by Tokyo-based Takeda Pharmaceutical Company, will also face a price bump similar to that of Toripalimab. A box of 21 pills each containing 5mg of the drug is sold in China for around 7,500 yuan (US$1,050), according to Chinese medical news site Medical Valley. Its US wholesale price will be US$25,200 for the same amount of medication, according to a Takeda prescribing document, putting it at 24 times the cost in China”
(Published: 7:00am, 28 Nov, 2023) “HutchMed (China), in which Hong Kong conglomerate CK Hutchison Holdings holds a major stake, is poised to market its self-developed cancer drug “fruquintinib” in Japan and Europe, according to a top executive. |
well the previous precedence continues, get a major drug approval (in this case a blockbuster $1.2bn+ in annual sales) and the share price dives!
At least short positions are radically lower than they were a few months ago
Hopefully we will get Gastric Cancer approval in China soon and Savolitinib NDA submission in the U.S. in early 2024
Great progress, which continues to accelerate. |
The DB session will be more interesting today, esp the questions, although it is late breaking news so how much new information they are willing to say is likely to be limited.
The obvious questions are when do they expect EU and JPN approvals, what are the milestone payments for these events and further details of the pricing in US - that may be too early or not their call. |
Perhaps today's Deutsche Bank ADR Virtual Investor presentation will help change the share price direction after the news?
HUTCHMED (China) Ltd. (Nasdaq/AIM: HCM | HKEX: 13)
11/09/2023 8:30PM - 9:00PM |
yes, we did it! and just like the day Frquintinib was approved in China, the share price dropped.... |
M&G have closed their entire short position in HK |
Let's hope the trend continues! The PDUFA news is getting closer and closer. Would be wonderful if we make it past 400p in the not too distant future. |
Well that's a 52 week intraday high this morning,an 18 month high in fact.This stock makes cryptocurrencies look like steady eddies. |
only 7 weeks until PDUFA |
lovely! we also have confirmation that the FDA has completed their inspection of the new factory |
RNS just dropped: "HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan...Alongside our partner Takeda, we are pleased to take this key step towards bringing fruquintinib to patients in Japan,” |
I assume they will hit the clinical development milestones in the corporate presentation….as they can reasonably predict when there will be news.
The remaining 2023 news that I am interested in is the FDA approval decision, also I think we can expect news of a Takeda Fruq Gastric Cancer trial in Japan and Korea as they are potentially large markets behind China for that treatment.
Further price moving news would be a new partnership for Suru or one of the new candidates going to enter approval (Sovlep/Amdiz)…;in theory these could happen at any time…..I think they need another deal in the next 12m to demonstrate the Takeda deal is not a one off…..I would like it to be IPSEN or Takeda to deepen these relationships. |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
